BRPI0410908A - derivados phi p 5a com reduzida alergenicidade e reatividade conservada para célula t - Google Patents

derivados phi p 5a com reduzida alergenicidade e reatividade conservada para célula t

Info

Publication number
BRPI0410908A
BRPI0410908A BRPI0410908-2A BRPI0410908A BRPI0410908A BR PI0410908 A BRPI0410908 A BR PI0410908A BR PI0410908 A BRPI0410908 A BR PI0410908A BR PI0410908 A BRPI0410908 A BR PI0410908A
Authority
BR
Brazil
Prior art keywords
phi
conserved
derivatives
reactivity
cell reactivity
Prior art date
Application number
BRPI0410908-2A
Other languages
English (en)
Inventor
Martin Wald
Oliver Cromwell
Andreas Nandy
Helga Kahlert
Bernhard Weber
Helmut Fiebig
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0410908A publication Critical patent/BRPI0410908A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"DERIVADOS PHI P 5A COM REDUZIDA ALERGENICIDADE E REATIVIDADE CONSERVADA PARA CéLULA T". A presente invenção refere-se a preparação e uso de variantes de alérgeno do grupo 5 de Pooideae que são caracterizados por reduzida reatividade a IgE, comparado com os alérgenos do tipo selvagem conhecidos, e ao mesmo tempo, por reatividade substancialmente conservada com linfócitos T. Essas variantes de alérgeno hipoalergênicas podem ser empregadas para imunoterapia específica (hipossensibização) de pacientes com alergia a pólen de grama ou para imunoterapia preventiva de alergias ao pólen de grama.
BRPI0410908-2A 2003-06-04 2004-05-06 derivados phi p 5a com reduzida alergenicidade e reatividade conservada para célula t BRPI0410908A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10325508 2003-06-04
PCT/EP2004/004848 WO2004108758A1 (de) 2003-06-04 2004-05-06 Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität

Publications (1)

Publication Number Publication Date
BRPI0410908A true BRPI0410908A (pt) 2006-06-27

Family

ID=33494849

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410908-2A BRPI0410908A (pt) 2003-06-04 2004-05-06 derivados phi p 5a com reduzida alergenicidade e reatividade conservada para célula t

Country Status (13)

Country Link
US (3) US8628946B2 (pt)
EP (3) EP1629006B1 (pt)
JP (2) JP4782671B2 (pt)
CN (1) CN1798763B (pt)
AT (1) ATE513848T1 (pt)
AU (1) AU2004245184B2 (pt)
BR (1) BRPI0410908A (pt)
CA (1) CA2528053C (pt)
ES (3) ES2434720T3 (pt)
PL (2) PL2272863T3 (pt)
PT (3) PT2272863E (pt)
RU (1) RU2368620C2 (pt)
WO (1) WO2004108758A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR779201A0 (en) 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
JP4782671B2 (ja) * 2003-06-04 2011-09-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減したアレルギー誘発性および保持されたＴ細胞反応性を有するＰｈｌｐ５ａ誘導体
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CA2786936A1 (en) 2010-01-14 2011-07-21 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
KR20240055084A (ko) 2021-09-13 2024-04-26 라이프 테크놀로지스 코포레이션 유전자 편집 도구

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736362A (en) * 1990-10-26 1998-04-07 The University Of Melbourne Ryegrass pollen allergen
DE19713001A1 (de) * 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
DE19918682A1 (de) * 1999-04-23 2000-10-26 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens
IT1318692B1 (it) * 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche di phleum pratense.
PL214225B1 (pl) * 2000-11-16 2013-07-31 Alk Abello As Zrekombinowany alergen, zastosowanie zrekombinowanego alergenu, kompozycja farmaceutyczna, sposób przygotowania kompozycji farmaceutycznej, sposób przygotowania zrekombinowanego alergenu, sekwencja DNA kodujaca zrekombinowany alergen, wektor ekspresyjny, komórka gospodarza oraz sposób produkcji zrekombinowanego zmutowanego alergenu
AUPR779201A0 (en) * 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
JP4782671B2 (ja) * 2003-06-04 2011-09-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減したアレルギー誘発性および保持されたＴ細胞反応性を有するＰｈｌｐ５ａ誘導体

Also Published As

Publication number Publication date
WO2004108758A1 (de) 2004-12-16
ES2434720T3 (es) 2013-12-17
US20140255434A1 (en) 2014-09-11
PT1629006E (pt) 2011-09-28
EP2272863A1 (de) 2011-01-12
PT2272863E (pt) 2013-01-30
PL2287180T3 (pl) 2013-12-31
PT2287180E (pt) 2013-10-31
PL2272863T3 (pl) 2013-03-29
ES2367633T3 (es) 2011-11-07
US20160207967A1 (en) 2016-07-21
EP2287180B9 (de) 2013-11-06
JP4782671B2 (ja) 2011-09-28
ATE513848T1 (de) 2011-07-15
CA2528053C (en) 2014-08-12
ES2397778T3 (es) 2013-03-11
EP1629006B1 (de) 2011-06-22
JP2007536893A (ja) 2007-12-20
RU2005141524A (ru) 2006-09-10
US9522938B2 (en) 2016-12-20
US8628946B2 (en) 2014-01-14
CN1798763A (zh) 2006-07-05
US20100158955A1 (en) 2010-06-24
JP2011041566A (ja) 2011-03-03
RU2368620C2 (ru) 2009-09-27
AU2004245184B2 (en) 2011-03-24
CA2528053A1 (en) 2004-12-16
AU2004245184A1 (en) 2004-12-16
EP2287180A1 (de) 2011-02-23
EP2287180B1 (de) 2013-08-07
EP2272863B1 (de) 2012-10-31
JP5363441B2 (ja) 2013-12-11
CN1798763B (zh) 2010-05-26
EP1629006A1 (de) 2006-03-01

Similar Documents

Publication Publication Date Title
US12516116B2 (en) Homodimeric protein constructs
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
NO20071609L (no) Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
NO20063026L (no) Antistoffer
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
UA95329C2 (ru) Собачий тимусный стромальный лимфопоэтин и его применение
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
ATE513848T1 (de) Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität
EP1219301A1 (en) Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
BR0313135A (pt) Epìtopos de células t em eritropoietina
JP2016513963A5 (pt)
PT1768996E (pt) Variantes dos alergénios do grupo 1 das poaceae com alergenecidade reduzida e mantendo a reactividade das células t
DE602006009077D1 (de) Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung
WO2013011184A3 (es) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
WO2006075253A3 (en) Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
PL400683A1 (pl) Sekwencja DNA oraz sposób otrzymywania rekombinowanego alergenu pylku traw PHL P4
Morrison et al. Contribution of advances in immunology to vaccine development
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
WO2004113361A3 (en) Novel prokineticin receptor isoforms and methods of use
Taechaudomtavorn The interaction of paramyxovirus membrane protein with actin: a novel model to study virus-induced autoimmunity.
WO2007042326A3 (en) Neisseria meningitidis antigens
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]